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 Amylin deposition in 
diabetic nephropathy
Many patients with diabetes develop 
amyloidosis of the islets. When the 
amyloid protein was purifi ed, it was 
found to be largely composed of a 
previously unknown peptide, and it 
was named amylin or islet amyloid 
peptide. Th is protein is present in the 
insulin-containing granules and is 
secreted with insulin. It can polymerize 
to form amyloid fi brils, and these can 
induce apoptosis of the β-islet cells. 
Gong et al. studied the renal biopsies of 
a large number of patients with diabetic 
nephropathy. Almost half of the patients 
showed amylin deposition, especially 
in the expanded mesangium of the 
diabetic glomeruli, as well as in the 
nodules that characterize Kimmelstiel-
Wilson disease. Th e deposition 
correlated with disease severity, and 
amylin was not seen to any extent in 
other glomerular diseases. Given that 
amylin deposition has been suspected 
as an important cause of islet damage, 
the question arises of whether it is also 
involved in renal toxicity. Obviously 
more work needs to be done in this 
important area, but we now have a new 
target of investigation. See page 213.
 Excessive 
proliferation of PKD1 
tubular epithelial 
cells
Increased rates of tubular-cell 
proliferation in the cysts of polycystic 
kidneys are one of the major changes in 
these cells. As they describe in this issue, 
Parker et al. conditionally immortalized 
epithelial cells from the kidneys 
of normal patients and those with 
germline mutations in the polycystic 
kidney disease 1 (PKD1) gene. Th ey 
found, as have others, that the PKD1 
cells had an increased sensitivity to 
cyclic AMP. In addition, they found 
that these cells proliferated to a greater 
extent in the presence of insulin-like 
growth factor-1 (IGF-1), a factor that 
has been implicated in cyst formation 
in rodent models of PKD. IGF-1 is 
known to signal through a pathway 
that includes phosphatidylinositol-
3-kinase. Downstream eff ectors of 
this pathway include the kinases Raf 
and Ras, and these authors found that 
inhibition of these enzymes prevented 
the proliferation induced by IGF-1 in 
the PKD cells. Th ese studies raise the 
possibility that targeting these kinases 
might be a useful method for reducing 
the rate of cyst enlargement in PKD. 
See page 157.
 Incidence of acute 
renal failure in the 
general population
We all know from making rounds 
that acute renal failure is a common 
condition, but what is its real incidence 
in the general population? Most 
previous studies attempted to fi nd 
the disease frequency in hospital-
based populations and hence were 
confounded by the variable thresholds 
for admission in diff erent locales. As 
they report in this issue, Hsu et al. 
studied this matter among members of 
the Kaiser Permanente health system 
in northern California, which is a large 
health-care delivery system. Changes 
in serum creatinine were used for 
diagnosis. Th e numbers are higher than 
one expects; for acute renal failure not 
requiring dialysis, the incidence was 
about 300 per 100,000 person-years and 
almost doubled in the 7-year period 
of observation. For those requiring 
dialysis, it was about 20 per 100,000 
person-years, increasing to about 30. 
Th is should make an excellent database 
for further study, especially to identify 
the reasons for the apparent increase 
in incidence over such a short time. 
See page 208.
